Insider Purchases: Inside the Buy

Tag: precision medicine

Editorial illustration for Ionis Pharmaceuticals (IONS), depicting RNA therapeutics, genetic medicine, biotechnology research, clinical innovation, insider buying, financial market volatility, DNA sequencing, and long-term healthcare investing.

🧬 Ionis Pharmaceuticals (IONS): The RNA Arbitrage — $2.1B Cash, $1M Insider Buy, and the Post-Trial Collapse

Ionis Pharmaceuticals (NASDAQ: IONS) lost billions in market value after a disappointing clinical trial—but one director immediately bought more than $1 million worth of shares. Is Wall Street missing the bigger RNA platform story? Here's the full analysis.

Read entire article

Tags: antisense RNA, biotech pipeline, biotech platform, biotech research, biotechnology investing, BiotechStocks, buy or sell IONS stock, clinical trials, Dawnzera, FDA, featured-insiders, Fred's Take, FUNanc1al, FUNStock, genomic medicine, growth stocks, healthcare innovation, healthcare stocks, hub-insiders, insider buying, insider purchases, InsiderBuying, Ionis Pharmaceuticals, IonisPharmaceuticals, IONS, long term investing, MichaelHayden, molecular medicine, NASDAQ, pharmaceutical stocks, precision medicine, risks buying IONS stock, RNA medicine, RNA therapeutics, RNATherapeutics, ShortSqueeze, Spinraza, stock market, Tryngolza, value investing, why buy IONS stock
Biotechnology laboratory where artificial intelligence designs therapeutic antibodies, featuring DNA helices, glowing neural-network interfaces, hair follicle imagery, and an upward stock chart symbolizing Absci's AI-powered drug discovery platform.

🧬 Absci (ABSI): A Director Bought After a 5× Rally. Here's Why the Story May Still Be in Its Early Innings.

When FUNanc1al first highlighted Absci around $4.18, the thesis centered on insider buying and an overlooked AI-biotech platform. Today the stock has nearly tripled, Eli Lilly has invested $100 million, institutions own over 80%, and another director is buying shares. Here's why the story may still be in its early innings.

Read entire article

Tags: ABS-201, ABS201, Absci, AbsciCorp, ABSI, antibody discovery, BiotechStocks, buy or sell ABSI, clinical-stage biotech, Eli Lilly, EliLilly, featured-insiders, FUNanc1al, FunStock, GenerativeAI, genomics, hair loss treatment, HairRegrowth, hub-insiders, insider buying, InsiderBuying, Mary Szela, MarySzela, NASDAQ, precision medicine, risks buying ABSI, SeanMcClain, ShortSqueeze, why buy ABSI